| CME
- Peer-to-Peer Dialogue
Program Title: Drug Therapy #3
This educational activity is sponsored by The France Foundation, and is supported by an educational grant from InterMune.
Release/Expiration Dates
This activity is eligible for CME credit from November 2007 through November 30, 2008.
Needs Statement
This activity has been planned in accordance with the need to provide pulmonologists, pathologists, and radiologists with education in idiopathic pulmonary fibrosis.
Educational Activity Objectives
Upon completion of this course, the participants should be able to:
- Manage patients through appropriate clinical trial enrollment as well as compliance with the terms of participation
Target Audience
The target audience for this activity is pulmonologists, pathologists, and radiologists.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Statement(s)
Physicians
The France Foundation designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Faculty Disclosure
It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty involved in this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a faculty member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.
Paul W. Noble, MD, FCCP, has served as a consultant for Actelion, Boehringer Ingelheim, InterMune, Johnson & Johnson, Novartis, and Stromedix. He is a speaker for InterMune, and is a Steering Committee member for InterMune and Boehringer Ingelheim.
Glenn D. Rosen, MD, serves as a speaker for InterMune.
Steven A. Sahn, MD, is an investigator and serves on the medical advisory board of InterMune.
Commercial Support Acknowledgment
This activity is supported by an educational grant from InterMune.
|
